Clinical Trial Update: Effects of Once and Twice Daily Dosing Regimen of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-040) [Phase 1]

View source ↗

Summary

Phase 1 trial update evaluating once vs twice daily dosing of ertugliflozin (MK-8835) in adults with type 2 diabetes; results completed with posted results in 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Ertugliflozin (ertugliflozin)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Diabetes Mellitus, Type 2, Adult | Phase 1 | Status: COMPLETED | Results posted: 2018-11-07